ESTRO 35 2016 _____________________________________________________________________________________________________ clinical constraints) and overdose comparable to the nominal case. Doses to organs at risk were similar for the three plans in both patients.
Material and Methods:
Based on treatment plans of 7 previously treated patients, the clinical protocol, and physician's treatment goals and priorities, our in-house developed system for fully automated, multi-criterial plan generation was configured to generate VMAT plans for advanced stage NSCLC patients without human interaction. For 41 independent patients, treated between January and August 2015, automatic plan generation was then compared with manual plan generation, as performed in clinical routine. Differences in PTV coverage, dose conformality R50 (the ratio between the total volume receiving at least 50% of the prescribed dose and the PTV volume) and sparing of organs at risk were quantified, and their statistical significance was assessed using a Wilcoxon test.
Results: For 35 out of 41 patients (85%), the automatically generated VMAT plans were clinically acceptable as judged by two physicians. Compared to the manually generated plans, they considered the quality of automatically generated plans superior for at least 67% of patients, due to a combination of better PTV coverage, dose conformality and sparing of lungs, heart and oesophagus (positive values in figure) . For the other acceptable plans plan quality was considered equivalent. On average, PTV coverage (V95) was improved by 1.1 % (p<0.001), the near-minimum dose in the PTV (D99) by 0.55 Gy (p=0.006) and the R50 by 12.4% (p<0.001). The mean lung dose was reduced by 0.86 Gy (4.6%, p<0.001), and the V20 of the lungs by 1.3 % (p=0.001). For some patients it was possible to improve PTV V95 by 3.8%, D99 by 3.3 Gy, to reduce mean lung dose by 3.0 Gy and V20 by 6.2%. All plans fulfilled the planning constraints for the spinal cord, heart and plexus. For the 6 automated VMAT plans that were initially not acceptable, it took a dosimetrist less than 10 minutes handson time to manually fine-tune the VMAT plan in our TPS to make it acceptable. In contrast, to generate a VMAT plan from scratch 3-4 hours were required. For 5 out of 10 patients with a PTV prescription dose of less than 66 Gy in the manual plan, we were able to escalate the tumour dose using automated planning. For two patients dose escalation from 60 Gy to 66 Gy was possible, for other patients from 60.5 Gy to 66 Gy, 45 Gy to 57.75 Gy, and 55 Gy to 60.5 Gy, respectively.
Conclusion:
Using our fully automated treatment planning procedure, clinically deliverable, high quality VMAT plans for advanced stage NSCLC patients may be generated without human interaction for the far majority of patients. When manual adjustments were required, they took very little hands-on time only. With automated planning, a higher tumour dose could be achieved for a subgroup of patients. Clinical introduction has been started.
OC-0267
Fully automated planning for non-coplanar CyberKnife prostate SBRT -comparison with automatic VMAT L. Rossi 1 Erasmus MC Cancer Institute, Radiation Oncology, Rotterdam, The Netherlands 1 , S. Breedveld 1 , S. Aluwini 1 , B. Heijmen 1 Purpose or Objective: In stereotactic body radiation therapy, high accuracy is required to deliver high fraction doses with steep dose gradients. Non-coplanar beam setups may improve plan quality. This can be realized with a robotic CyberKnife (CK, Accuray Inc, Sunnyvale, USA). Due to its tumor tracking features, CTV-PTV margins may be reduced compared to linac treatment. In previous works we have built and validated a system for fully automated, multi-criterial VMAT plan generation (iCycle/Monaco). Recently, we have extended the system with an option for fully automated plan generation for the CK (iCycle/Multiplan). In this study we have used fully automated plan generation for un-biased comparison of non-coplanar CK with coplanar VMAT at a linac, for prostate SBRT.
Material and Methods:
Our in-house iCycle system was first coupled to the Multiplan TPS that comes with the CK treatment unit. The iCycle/Multiplan and iCyle/Monaco systems were then configured for automated prostate SBRT plan generation for CK and linac-VMAT, respectively. Plans were then generated for 10 prostate SBRT patients, delivering 38 Gy in 4 fractions. Three clinically deliverable plans were automatically generated for each patient, one for CK with 3 mm PTV margin, and two for VMAT with 3 and 5 mm PTV margin, respectively.
Results: With automated planning, high quality CK and VMAT plans could be generated without user dependency and trialand-error approach. PTV coverage was similar for the 3 approaches, with on average a V100% of 95.2, 95.4%, and 94.1% for CK, VMAT-3mm and VMAT-5mm. However, for some VMAT plans with 5mm margin, coverage > 95% was not feasible. Mean values for rectum D1cc were 26.1, 28.5, and 34.3 Gy, for rectum Dmean 6.3, 7.1, and 10.8 Gy, for bladder D1cc 37.7, 37.3, and 39.4 Gy, and for bladder Dmean 8.7, 7.5, and 9.2 Gy, for CK, VMAT-3mm and VMAT-5mm, respectively. Rectum doses were lower with CK compared to VMAT-3mm (p = 0.015 and p = 0.08 for rectum D1cc and Dmean) and highly decreased compared to VMAT-5mm (p = 0.007 and 0.008). Bladder sparing worsened slightly with CK compared to VMAT-3mm, but this was not statistically significant. No relevant differences were found for other OARs. With CK, the low-medium dose bath was reduced compared to VMAT: V10Gy = 1157 .5, 1525 .6, 1741 .0 cc, for CK, VMAT-3mm and VMAT-5mm, respectively, with p = 0.007 and p=0.008 for CK comparing to VMAT 3 and 5 mm.
Conclusion: The first system for automated generation of clinically deliverable Cyberknife plans was built and used for unbiased plan comparison with VMAT at a linac. Optimized non-coplanar setups showed better rectum sparing compared to VMAT plans. This difference was especially large with the smaller CK CTV-PTV margin, possible with CyberKnife tumor tracking feature. Purpose or Objective: Recently, iCycle/Monaco, a system for fully automated, multi-criterial plan generation, consisting of the in-house iCycle optimizer and Monaco (Elekta AB, Stockholm, Sweden) has been developed. Sofar, the system was only validated in a single institution. In this study, iCycle/Monaco was validated in 4 independent centers for prostate cancer VMAT. Hypothesis of the study was that automatically generated plans had similar or superior quality compared to plans generated by manual planning in clinical routine, using the Monaco TPS only.
OC-0268 Fully automated VMAT plan generation -an international multi-institutional validation study B. Heijmen

Material and Methods:
For each of the 4 centers, plans of 10 recently treated patients were used to configure iCycle/Monaco. For 20 independent patients, manually generated VMAT plans (MANplan) were then compared with automatically generated VMAT plans (AUTOplan). Plans were compared using dose-volume parameters and by 'blind' scoring by treating physicians. The scoring of the plans by physicians was performed in 2 sessions: A) the in total 40 anonymized plans (20 AUTO, 20 MAN) were evaluated in random order to assess clinical acceptability, B) for each of the 20 patients, the AUTOplan and MANplan were compared to select the most favorable plan. In these comparisons, plans could be scored as i) of higher quality with a clinically relevant difference, ii) of higher quality but with a low clinical impact, or iii) of similar quality. In one participating center, plan scoring was performed independently by 2 physicians. Results: A total of 200 separate plan evaluations and 100 plan comparisons were made in this study. In the separate plan evaluations, 100% of MANplans and 98% of AUTOplans were clinically acceptable. The 2 AUTOplans that were not clinically acceptable had too high bowel dose, which was due to the absence of patients with small bowel delineation among the patients used for configuration of iCycle/Monaco in 2 centers. For 38/100 plan comparisons, the AUTOplan was considered superior to the MANplan, with high clinical relevance. Only in 9 comparisons, the MANplan was superior with high relevance for the patient. In all other comparisons, differences were absent or of minor clinical relevance (Figure) . With similar PTV coverage, dose delivery to OARs was on average lower for the AUTOplans: -14.8%, -24.6%, and -14.6% for rectum V75, V60, and Dmean (p=0.001, p<0.001, p<0.001), and -5.1% for bladder Dmean (p=0.009).
Frequency histogram showing the scores for 100 comparisons of an automatically (AUTO) and a manually (MAN) generated plan.
Conclusion:
In an international, multi-institutional setting, automatic planning for prostate cancer has proven to be overall superior to manual planning. Automated planning avoids planning workload and contributes to standardized radiotherapy treatment with high plan quality. Purpose or Objective: Simultaneously integrated boost (SIB) used in many sites, replanning is not made. In SIB of intensity-modulated radiotherapy (IMRT), doses per fraction are often unconventional, because of equal fractions treating multiple targets. We assessed sequential SIB (SEQ-SIB) to resolve the problem. The purpose of this study is to compare dosimetric parameters of SEQ-SIB with those of SIB using deformable imaging registration (DIR) for head and neck cancer patients.
Material and Methods: Subjects were 10 cases HNC treated with IMRT at our institute in 2014. In all cases, high-risk planning target volume (PTVboost) was based on the primary tumor and clinical lymph node metastases, while PTVelective(PTVel) included bilateral cervical nodal areas. The D95 was defined as the prescribed dose. For SIB, doses were 66 and 54 Gy in 30 fractions to PTVboost and PTVel, respectively. For SEQ-SIB, they were 55 Gy to PTVboost and 50 Gy to PTVel in 25 fractions using SIB, followed by 11 Gy in 5 fractions to PTVboost.We chose to maintain the size of the
